Ratakorn Srisuttee1, Areeya Arayataweegool2, Patnarin Mahattanasakul3,4, Napadon Tangjaturonrasme3, Virachai Kerekhanjanarong3, Somboon Keelawat5, Apiwat Mutirangura2, Nakarin Kitkumthorn6. 1. Faculty of Medicine, King Mongkut's Institute of Technology Ladkrabang, Bangkok, 10520, Thailand. 2. Center of Excellence in Molecular Genetics of Cancer and Human Diseases, Department of Anatomy, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand. 3. Department of Otolaryngology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand. 4. Department of Otolaryngology, Head and Neck Surgery, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, 10330, Thailand. 5. Department of Pathology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand. 6. Department of Oral Biology, Faculty of Dentistry, Mahidol University, Payathai Rd., Ratchathewi, Bangkok, 10400, Thailand. Nakarinkit@gmail.com.
Abstract
BACKGROUND: Oral squamous cell carcinoma (OSCC) is an aggressive human malignancy. Because of late diagnosis and recurrence of OSCC, the treatment of patients with OSCC is often ineffective. Thus, finding novel biomarkers of OSCC are essential. Here we derived a methylation marker by utilizing methylation microarray data and testing its capacity in cross-sectional study designed for OSCC detection and screening. METHODS: According to bioinformatics analysis of total of 27,578 cg sites, cg22881914 of Nidogen 2 (NID2) methylation was selected for evaluation. Next, we confirmed the methylation status by bisulfite sequencing from the microdissected OSCC cells in comparison with the microdissected oral epithelia. Subsequently, we developed a simple technique using real-time PCR with the specific probe to examine the ability for the detection of OSCC in the oral epithelial samples, which included 103 oral rinse and 82 oral swab samples. RESULTS: Based on the comparison of microdissected tissue, cg22881914 of NID2 was proved to be methylated in most OSCC cells but unmethylated in the normal oral epithelia. Furthermore, the methylated NID2-relied quantitative PCR approach has demonstrated that this marker assists in distinguishing among patients with OSCC from normal oral epithelia, smokers, and patients with oral lichen planus using the non-invasive oral rinse and swab samples. CONCLUSIONS: Specific methylation at cg22881914 of NID2 of OSCC could be used as an important potential marker for detecting OSCC. Thus, to certify the utility of this marker, further studies with a larger sample size are needed.
BACKGROUND:Oral squamous cell carcinoma (OSCC) is an aggressive humanmalignancy. Because of late diagnosis and recurrence of OSCC, the treatment of patients with OSCC is often ineffective. Thus, finding novel biomarkers of OSCC are essential. Here we derived a methylation marker by utilizing methylation microarray data and testing its capacity in cross-sectional study designed for OSCC detection and screening. METHODS: According to bioinformatics analysis of total of 27,578 cg sites, cg22881914 of Nidogen 2 (NID2) methylation was selected for evaluation. Next, we confirmed the methylation status by bisulfite sequencing from the microdissected OSCC cells in comparison with the microdissected oral epithelia. Subsequently, we developed a simple technique using real-time PCR with the specific probe to examine the ability for the detection of OSCC in the oral epithelial samples, which included 103 oral rinse and 82 oral swab samples. RESULTS: Based on the comparison of microdissected tissue, cg22881914 of NID2 was proved to be methylated in most OSCC cells but unmethylated in the normal oral epithelia. Furthermore, the methylated NID2-relied quantitative PCR approach has demonstrated that this marker assists in distinguishing among patients with OSCC from normal oral epithelia, smokers, and patients with oral lichen planus using the non-invasive oral rinse and swab samples. CONCLUSIONS: Specific methylation at cg22881914 of NID2 of OSCC could be used as an important potential marker for detecting OSCC. Thus, to certify the utility of this marker, further studies with a larger sample size are needed.
Authors: Óscar Rapado-González; José Luis López-Cedrún; Rafael López-López; Ana María Rodríguez-Ces; María Mercedes Suárez-Cunqueiro Journal: J Clin Med Date: 2021-04-29 Impact factor: 4.241
Authors: Julianna K Bronk; Chiraag Kapadia; Xiaogang Wu; Bhavana V Chapman; Rui Wang; Tatiana V Karpinets; Xingzhi Song; Andrew M Futreal; Jianhua Zhang; Ann H Klopp; Lauren E Colbert Journal: PLoS One Date: 2022-10-06 Impact factor: 3.752
Authors: Natalia Birknerova; Veronika Mancikova; Evan David Paul; Jan Matyasovsky; Pavol Cekan; Vladimir Palicka; Helena Parova Journal: Cancers (Basel) Date: 2022-10-06 Impact factor: 6.575